Joel Greenblatt’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$55.7M Buy
1,524,310
+174,845
+13% +$6.34M 0.11% 186
2026
Q2
$47.8M Sell
1,349,465
-66,626
-5% -$1.97M 0.11% 204
2026
Q1
$39.2M Buy
1,416,091
+490,898
+53% +$12.6M 0.12% 188
2025
Q4
$20.1M Buy
925,193
+594,718
+180% +$11.7M 0.07% 387
2025
Q3
$5M Buy
330,475
+291,326
+744% +$3.61M 0.02% 778
2025
Q2
$441K Buy
39,149
+122
+0.3% +$1.32K ﹤0.01% 1358
2025
Q1
$394K Hold
39,027
– – ﹤0.01% 1297
2024
Q4
$462K Hold
39,027
– – ﹤0.01% 1146
2024
Q3
$450K Sell
39,027
-510
-1% -$5.81K ﹤0.01% 1138
2024
Q2
$418K Buy
+39,537
New +$433K 0.01% 1129

Other funds holding ROIV

Joel Greenblatt's ROIV Position: Q3 2026 in Review

Joel Greenblatt increased its Roivant Sciences (ROIV) stake by 13% in Q3 2026, buying an estimated $6.34M and bringing the position to 1,524,310 shares worth $55.7M. The position accounts for 0.11% of the portfolio, ranked #186.

Joel Greenblatt first reported a position in ROIV in Q2 2024 and has held it in 10 quarters since. 516 funds tracked by Wall St. Rank hold ROIV as of Q3 2026.

  • Joel Greenblatt held 1,524,310 shares of Roivant Sciences worth $55.7M as of Q3 2026.
  • Joel Greenblatt bought 174,845 Roivant Sciences shares in Q3 2026, an estimated $6.34M.
  • Roivant Sciences made up 0.11% of Joel Greenblatt's portfolio in Q3 2026, its #186 holding.
  • Joel Greenblatt first reported a position in Roivant Sciences in Q2 2024 and has held it in 10 quarters since.
  • 516 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2026.

Based on Gotham Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.